Michael Hallek, MD from the University of Cologne, Cologne, Germany discusses the potential benefits of biosimilars. Prof. Hallek suggests that they make the market more competitive, which in turn, might lower the price of drugs. He also talks about the difficulties associated with the production of biosimilars of proteins.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Making the market more competitive – the potential benefit of biosimilars
